Is Hims The Next Big Name In Peptides?

Is Hims The Next Big Name In Peptides?

Hims stock inched lower Tuesday, recovering from a late-Monday dive, as the telehealth giant seemingly moves closer to the peptide segment.

Hims & Hers' shift to branded obesity drugs drives wider quarterly loss

Hims & Hers stock drops 7% despite higher guidance: what went wrong?

Shares of Hims & Hers Health fell more than 7% in premarket trading on Tuesday after the telehealth company reported a wider-than-expected second-quarter loss, as investments in branded GLP-1 weight-loss treatments and international expansion weighed on profitability. The company reported a net loss of 37 cents per share for the quarter, compared with analysts' expectations for a loss of 1 cent per share, according to LSEG data. The weaker botto…